Tratamiento habitual con formoterol versus tratamiento habitual con salmeterol para el asma crónica: eventos adversos graves
Información
- DOI:
- https://doi.org/10.1002/14651858.CD007695.pub3Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 14 marzo 2012see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Vías respiratorias
- Copyright:
-
- Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
CJC: conception of the idea and co‐writing of protocol and review.
TL: co‐writing of the protocol and review.
Sources of support
Internal sources
-
St George's University of London, UK.
External sources
-
NIHR, UK.
Programme Grant
Declarations of interest
None known.
Acknowledgements
We acknowledge the assistance of Susan Hansen in obtaining the papers and extracting study details, Elizabeth Stovold for assistance with the update searches and of Matthew Cates with the protocol, and for input re physiology of beta‐agonist receptors. We thank Prof Haydn Walters for providing editorial review and we thank Linda Armstrong from Novartis for providing data on file for Vervloet 1998 and Gabbay 1998, and Joe Gray of AstraZeneca and Dr Everden for clarifying that there were no deaths in Everden 2004.
CRG Funding Acknowledgement: The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Airways Group.
Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.
Version history
| Published | Title | Stage | Authors | Version |
| 2012 Mar 14 | Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events | Review | Christopher J Cates, Toby J Lasserson | |
| 2009 Oct 07 | Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events | Review | Christopher J Cates, Toby J Lasserson | |
| 2009 Jul 08 | Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events | Protocol | Christopher J Cates, Toby J Lasserson | |
Differences between protocol and review
The 'Summary of findings' table was not mentioned in the protocol and has been constructed on the basis of the primary outcomes and asthma‐related SAEs. Adults and children have been described separately in the 'Summary of findings' table.
